+

SE0203065D0 - Gastric acid secretion inhibiting composition - Google Patents

Gastric acid secretion inhibiting composition

Info

Publication number
SE0203065D0
SE0203065D0 SE0203065A SE0203065A SE0203065D0 SE 0203065 D0 SE0203065 D0 SE 0203065D0 SE 0203065 A SE0203065 A SE 0203065A SE 0203065 A SE0203065 A SE 0203065A SE 0203065 D0 SE0203065 D0 SE 0203065D0
Authority
SE
Sweden
Prior art keywords
dosage form
gastric acid
acid secretion
inhibiting composition
treatment
Prior art date
Application number
SE0203065A
Other languages
English (en)
Inventor
Anders Pettersson
Christer Nystroem
Yvonne Haakansson
Original Assignee
Diabact Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diabact Ab filed Critical Diabact Ab
Priority to SE0203065A priority Critical patent/SE0203065D0/sv
Publication of SE0203065D0 publication Critical patent/SE0203065D0/sv
Priority to EP03748871A priority patent/EP1558288A1/en
Priority to AU2003267924A priority patent/AU2003267924C1/en
Priority to NZ539262A priority patent/NZ539262A/en
Priority to US10/531,598 priority patent/US7785626B2/en
Priority to KR1020057006582A priority patent/KR101139862B1/ko
Priority to MXPA05004118A priority patent/MXPA05004118A/es
Priority to CN2003801063027A priority patent/CN1726048B/zh
Priority to CA2501201A priority patent/CA2501201C/en
Priority to JP2004545135A priority patent/JP2006505566A/ja
Priority to PL03376178A priority patent/PL376178A1/xx
Priority to PCT/SE2003/001598 priority patent/WO2004035090A1/en
Priority to EP10075410A priority patent/EP2258341A3/en
Priority to RU2005114612/15A priority patent/RU2340358C2/ru
Priority to NO20052019A priority patent/NO20052019L/no
Priority to US11/544,750 priority patent/US7771747B2/en
Priority to US12/660,056 priority patent/US20100151013A1/en
Priority to JP2010288271A priority patent/JP2011057714A/ja
Priority to US13/355,935 priority patent/US20120121664A1/en
Priority to US13/621,423 priority patent/US20130017263A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0203065A 2002-10-16 2002-10-16 Gastric acid secretion inhibiting composition SE0203065D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0203065A SE0203065D0 (sv) 2002-10-16 2002-10-16 Gastric acid secretion inhibiting composition
RU2005114612/15A RU2340358C2 (ru) 2002-10-16 2003-10-15 Композиция, ингибирующая секрецию кислоты в желудке
CA2501201A CA2501201C (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
PL03376178A PL376178A1 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
NZ539262A NZ539262A (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
US10/531,598 US7785626B2 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
KR1020057006582A KR101139862B1 (ko) 2002-10-16 2003-10-15 위산 분비 억제 조성물
MXPA05004118A MXPA05004118A (es) 2002-10-16 2003-10-15 Composicion inhibidora de la secrecion de acido gastrico.
CN2003801063027A CN1726048B (zh) 2002-10-16 2003-10-15 抑制胃酸分泌的组合物
EP03748871A EP1558288A1 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
JP2004545135A JP2006505566A (ja) 2002-10-16 2003-10-15 胃酸分泌阻害組成物
AU2003267924A AU2003267924C1 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
PCT/SE2003/001598 WO2004035090A1 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
EP10075410A EP2258341A3 (en) 2002-10-16 2003-10-15 Gastric acid secretion inhibiting composition
NO20052019A NO20052019L (no) 2002-10-16 2005-04-26 Blanding for a inhibere sekresjon av magesyre
US11/544,750 US7771747B2 (en) 2002-10-16 2006-10-10 Gastric acid secretion inhibiting composition
US12/660,056 US20100151013A1 (en) 2002-10-16 2010-02-19 Gastric acid secretion inhibiting composition
JP2010288271A JP2011057714A (ja) 2002-10-16 2010-12-24 胃酸分泌阻害組成物
US13/355,935 US20120121664A1 (en) 2002-10-16 2012-01-23 Gastric Acid Secretion Inhibiting Composition
US13/621,423 US20130017263A1 (en) 2002-10-16 2012-09-17 Gastric acid secretion inhibiting composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203065A SE0203065D0 (sv) 2002-10-16 2002-10-16 Gastric acid secretion inhibiting composition

Publications (1)

Publication Number Publication Date
SE0203065D0 true SE0203065D0 (sv) 2002-10-16

Family

ID=20289290

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203065A SE0203065D0 (sv) 2002-10-16 2002-10-16 Gastric acid secretion inhibiting composition

Country Status (14)

Country Link
US (5) US7785626B2 (sv)
EP (2) EP1558288A1 (sv)
JP (2) JP2006505566A (sv)
KR (1) KR101139862B1 (sv)
CN (1) CN1726048B (sv)
AU (1) AU2003267924C1 (sv)
CA (1) CA2501201C (sv)
MX (1) MXPA05004118A (sv)
NO (1) NO20052019L (sv)
NZ (1) NZ539262A (sv)
PL (1) PL376178A1 (sv)
RU (1) RU2340358C2 (sv)
SE (1) SE0203065D0 (sv)
WO (1) WO2004035090A1 (sv)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ES2320438T7 (es) 2002-04-09 2013-02-14 Flamel Technologies Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2006026337A1 (en) * 2004-08-25 2006-03-09 Fairfield Clinical Trials, Llc Combination of a proton pump inhibitor and a h2 antagonist for the treatment of gastroesophageal reflux disease
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
EP1875911A4 (en) * 2005-04-28 2010-03-03 Eisai R&D Man Co Ltd STABILIZED COMPOSITION
PT1883396E (pt) 2005-05-18 2013-10-08 Centre Nat Rech Scient Administração colónica de adsorventes
JP5269595B2 (ja) * 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
JPWO2007074909A1 (ja) * 2005-12-28 2009-06-04 武田薬品工業株式会社 放出制御固形製剤
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
JP5233108B2 (ja) * 2006-10-24 2013-07-10 ゼリア新薬工業株式会社 ニザチジン含有医薬組成物
WO2009145905A1 (en) * 2008-05-30 2009-12-03 Pozen Inc. Dosage forms for the rapid and sustained elevation of gastric ph
US20110142905A1 (en) * 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
JP5878022B2 (ja) * 2009-02-23 2016-03-08 アデア ファーマスーティカルズ，インコーポレイテッド 抗コリン薬を具える放出制御組成物
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CA2772750A1 (en) * 2009-09-08 2011-03-17 Kyowa Chemical Industry Co., Ltd. Antacid and laxative tablet
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) * 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3302566A1 (en) * 2015-05-29 2018-04-11 Johnson & Johnson Consumer Inc. Use of organic citrus extract with high antimicrobial capacity as a preservative system in liquids, emulsions, suspensions, creams and antacids
CN105796532B (zh) * 2016-03-28 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种雷贝拉唑钠缓释胶囊及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN105944104B (zh) * 2016-06-17 2018-12-14 上海凯宝药业股份有限公司 一种治疗消化道溃疡的药物组合物
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. PROCEDURES AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF PHARMACEUTICAL ACTIVE SUBSTANCES
KR102006777B1 (ko) * 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
CA3095103A1 (en) 2018-04-27 2019-10-31 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form
WO2020040438A1 (ko) 2018-08-23 2020-02-27 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
DE3400014A1 (de) 1984-01-02 1985-07-18 Henkel KGaA, 4000 Düsseldorf Entschaeumer fuer waessrige dispersionen und loesungen von kunstharzen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE69131627T2 (de) 1990-06-20 2000-04-27 Astra Ab Soedertaelje Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5622717A (en) * 1991-12-17 1997-04-22 Fuisz Technologies Ltd. Ulcer prevention method using a melt-spun hydrogel
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
AU1434295A (en) 1993-12-14 1995-07-03 Neo-Concepts, Inc. Solid state power supply circuit for cold cathode lighting
US5407687A (en) 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
AU7166396A (en) * 1995-09-27 1997-04-17 United Defense, L.P. Integrated protective action system
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
DE19709897A1 (de) 1997-03-11 1998-09-17 Hoechst Ag Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
DE69837450T2 (de) * 1997-07-22 2007-08-23 Merck & Co., Inc. Alendronate zur Behandlung von Osteoporose
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
JP2000063280A (ja) * 1998-06-11 2000-02-29 Takeda Chem Ind Ltd 抗ヘリコバクタ―・ピロリ活性胃腸薬
PT1105105E (pt) 1998-08-12 2006-07-31 Altana Pharma Ag Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
ES2194515T3 (es) 1998-10-06 2003-11-16 Mars Uk Ltd Estereotipia en animales.
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6316469B1 (en) 2000-03-01 2001-11-13 Duke University Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease
US6483346B2 (en) * 2000-11-15 2002-11-19 Texas Instruments Incorporated Failsafe interface circuit with extended drain services
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra

Also Published As

Publication number Publication date
RU2005114612A (ru) 2005-10-10
NO20052019L (no) 2005-06-15
US20060115530A1 (en) 2006-06-01
AU2003267924B2 (en) 2008-12-11
WO2004035090A1 (en) 2004-04-29
NZ539262A (en) 2008-04-30
RU2340358C2 (ru) 2008-12-10
CA2501201C (en) 2013-01-08
CN1726048B (zh) 2012-05-30
AU2003267924A1 (en) 2004-05-04
US20120121664A1 (en) 2012-05-17
JP2006505566A (ja) 2006-02-16
US7785626B2 (en) 2010-08-31
MXPA05004118A (es) 2005-10-05
CN1726048A (zh) 2006-01-25
US7771747B2 (en) 2010-08-10
US20070031497A1 (en) 2007-02-08
CA2501201A1 (en) 2004-04-29
PL376178A1 (en) 2005-12-27
EP2258341A2 (en) 2010-12-08
AU2003267924C1 (en) 2012-09-20
KR20050083770A (ko) 2005-08-26
US20100151013A1 (en) 2010-06-17
JP2011057714A (ja) 2011-03-24
US20130017263A1 (en) 2013-01-17
NO20052019D0 (no) 2005-04-26
KR101139862B1 (ko) 2012-07-03
EP2258341A3 (en) 2012-08-29
EP1558288A1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
SE0203065D0 (sv) Gastric acid secretion inhibiting composition
DK1389109T3 (da) Sammensætning til hæmning af mavesyreafsondring
TR201903603T4 (tr) Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
RS115104A (en) Pramipexole once-daily dosage form
DK1414451T3 (da) Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
NO20073802L (no) Leuprolidacetat og acetylkolinsteraseinhibitor eller NMDA-reseptorantagonister for behandlingen av Alzheimers sykdom
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2009017624A3 (en) Compositions with enhanced bioavailability and fast acting inhibitor of gastric acid secretion
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
RS20050470A (en) Solid drug for oral use
DK1559431T3 (da) Farmaceutisk sammensætning til thrombinpeptidderivater
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO1999065513A3 (en) Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
DE602006021348D1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
MX2007005238A (es) Una composicion veterinaria transmucosal que comprende detomidina.
WO2008002567A3 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
RS20050796A (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
DK2061444T3 (da) Sammensætninger og fremgangsmåder til behandling, kontrol, reducering, forbedring eller forebyggelse af allergi
WO2006050472A3 (en) Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载